313 related articles for article (PubMed ID: 16982759)
21. Proteolytic activation of pro-macrophage-stimulating protein by hepsin.
Ganesan R; Kolumam GA; Lin SJ; Xie MH; Santell L; Wu TD; Lazarus RA; Chaudhuri A; Kirchhofer D
Mol Cancer Res; 2011 Sep; 9(9):1175-86. PubMed ID: 21875933
[TBL] [Abstract][Full Text] [Related]
22. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.
McClaine RJ; Marshall AM; Wagh PK; Waltz SE
Neoplasia; 2010 Aug; 12(8):650-8. PubMed ID: 20689759
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic signaling pathways activated by RON receptor tyrosine kinase.
Danilkovitch-Miagkova A
Curr Cancer Drug Targets; 2003 Feb; 3(1):31-40. PubMed ID: 12570659
[TBL] [Abstract][Full Text] [Related]
24. RON, a tyrosine kinase receptor involved in tumor progression and metastasis.
Camp ER; Liu W; Fan F; Yang A; Somcio R; Ellis LM
Ann Surg Oncol; 2005 Apr; 12(4):273-81. PubMed ID: 15827676
[TBL] [Abstract][Full Text] [Related]
25. The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer.
Millar R; Kilbey A; Remak SJ; Severson TM; Dhayade S; Sandilands E; Foster K; Bryant DM; Blyth K; Coffelt SB
Mol Oncol; 2020 Aug; 14(8):1868-1880. PubMed ID: 32484599
[TBL] [Abstract][Full Text] [Related]
26. Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.
Wang MH; Yao HP; Zhou YQ
Acta Pharmacol Sin; 2006 Jun; 27(6):641-50. PubMed ID: 16723080
[TBL] [Abstract][Full Text] [Related]
27. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
Vanderwerff BR; Church KJ; Kawas LH; Harding JW
Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
[TBL] [Abstract][Full Text] [Related]
28. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
29. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.
Wang MH; Padhye SS; Guin S; Ma Q; Zhou YQ
Acta Pharmacol Sin; 2010 Sep; 31(9):1181-8. PubMed ID: 20694025
[TBL] [Abstract][Full Text] [Related]
30. Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.
Shen J; Vil MD; Prewett M; Damoci C; Zhang H; Li H; Jimenez X; Deevi DS; Iacolina M; Kayas A; Bassi R; Persaud K; Rohoza-Asandi A; Balderes P; Loizos N; Ludwig DL; Tonra J; Witte L; Zhu Z
Neoplasia; 2009 Jun; 11(6):594-604. PubMed ID: 19484148
[TBL] [Abstract][Full Text] [Related]
31. Ron-receptor tyrosine kinase in tumorigenesis and metastasis.
Leonis MA; Thobe MN; Waltz SE
Future Oncol; 2007 Aug; 3(4):441-8. PubMed ID: 17661719
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
Piloto O; Levis M; Huso D; Li Y; Li H; Wang MN; Bassi R; Balderes P; Ludwig DL; Witte L; Zhu Z; Hicklin DJ; Small D
Cancer Res; 2005 Feb; 65(4):1514-22. PubMed ID: 15735040
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
[TBL] [Abstract][Full Text] [Related]
34. RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity.
Guin S; Yao HP; Wang MH
Mol Pharm; 2010 Apr; 7(2):386-97. PubMed ID: 20039696
[TBL] [Abstract][Full Text] [Related]
35. Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein.
Chao KL; Gorlatova NV; Eisenstein E; Herzberg O
J Biol Chem; 2014 Oct; 289(43):29948-60. PubMed ID: 25193665
[TBL] [Abstract][Full Text] [Related]
36. The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.
Tong X; Zhang X; Fan J; Tong Y; Li S; Jin J; Yao H
Cancer Biol Ther; 2013 Apr; 14(4):370-7. PubMed ID: 23360784
[TBL] [Abstract][Full Text] [Related]
37. The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation.
Angeloni D; Danilkovitch-Miagkova A; Miagkov A; Leonard EJ; Lerman MI
J Biol Chem; 2004 Jan; 279(5):3726-32. PubMed ID: 14597639
[TBL] [Abstract][Full Text] [Related]
38. The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression.
Kretschmann KL; Eyob H; Buys SS; Welm AL
Curr Drug Targets; 2010 Sep; 11(9):1157-68. PubMed ID: 20545605
[TBL] [Abstract][Full Text] [Related]
39. The prostate transglutaminase, TGase-4, coordinates with the HGFL/MSP-RON system in stimulating the migration of prostate cancer cells.
Jiang WG; Ye L; Ablin RJ; Kynaston HG; Mason MD
Int J Oncol; 2010 Aug; 37(2):413-8. PubMed ID: 20596668
[TBL] [Abstract][Full Text] [Related]
40. Macrophage stimulating protein (MSP) binds to its receptor via the MSP beta chain.
Wang MH; Julian FM; Breathnach R; Godowski PJ; Takehara T; Yoshikawa W; Hagiya M; Leonard EJ
J Biol Chem; 1997 Jul; 272(27):16999-7004. PubMed ID: 9202013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
